GSK Bets $10.6 Billion on Lung Cancer Drugs for Resistant Tumors

GSK announced an all-cash acquisition of biotech firm Nuvalent for $10.6 billion on June 9, 2026. Nuvalent's drugs target lung cancers that have resisted earlier treatments. The price reflects confidence in a real gap: patients whose tumors have stopped responding to first-line therapy need options to sequence next. Regulatory approval of the lead drug, zidesamtinib, will determine whether that bet pays off.